Summary
The AI list contains multiple supplement/drug-safety and dosing-style claims that are not supported by the provided VASCEPA prescribing-information excerpts (e.g., specific interactions with garlic/ginkgo/ginseng/ginger/dong quai/vitamin E, and specific lab-testing and dosing limits). The label excerpts provided support only a general increased bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents, not named herbal supplements or specific vitamin E limits.
Category Scores
Accurate Statements
Some supplements can alter the blood-thinning effects of Vascepa.
Label excerpt 7.1 and 5.3 state VASCEPA is associated with increased bleeding risk and that incidence is greater with concomitant antithrombotic medications (e.g., aspirin, clopidogrel, or warfarin) and to monitor patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents for bleeding; this broadly supports a general caution about co-administered agents affecting bleeding risk.
Unsupported Statements
Garlic increases bleeding risk when taken with icosapent ethyl.
Provided excerpts do not mention garlic or any specific herbal supplement interaction.
Ginkgo biloba increases bleeding risk when taken with icosapent ethyl.
Provided excerpts do not mention ginkgo biloba or any specific herbal supplement interaction.
Fish oil supplements increase bleeding risk when taken with icosapent ethyl.
While the label discusses bleeding risk with concomitant antithrombotic medications and notes published studies with omega-3 fatty acids prolong bleeding time, the provided excerpts do not specifically state that additional fish oil supplements increase bleeding risk when taken with VASCEPA (beyond the general concomitant omega-3 evidence referenced in 7.1).
People taking garlic, ginkgo biloba, and fish oil supplements together with Vascepa should have their blood tested regularly.
The label excerpts only direct monitoring for bleeding with concomitant anticoagulants/antiplatelet agents; they do not recommend regular blood testing for these specific supplements.
Herbal products labeled as blood thinners can compound the anti-clotting action of Vascepa.
The label excerpts specify increased bleeding risk with concomitant antithrombotic medications and to monitor with anticoagulants/antiplatelet agents; they do not mention herbal products labeled as blood thinners or compound effects.
Dong quai can compound the anti-clotting action of Vascepa.
Provided excerpts do not mention dong quai.
Ginger can compound the anti-clotting action of Vascepa.
Provided excerpts do not mention ginger.
Ginseng can compound the anti-clotting action of Vascepa.
Provided excerpts do not mention ginseng.
Patients who use blood-thinner herbal products should tell their doctor before starting them when using Vascepa.
The label excerpts provided do not include this instruction for herbal products specifically (they mention monitoring with anticoagulants/antiplatelet agents).
Vitamin E in high doses widens blood vessels.
Provided excerpts do not discuss vitamin E effects on blood vessels.
Vitamin E in high doses reduces clotting.
Provided excerpts do not discuss vitamin E effects on clotting.
Combining vitamin E with Vascepa can lead to longer bleeding times.
Provided excerpts do not mention vitamin E or a specific bleeding-time effect from combining vitamin E with VASCEPA.
Patients usually need to limit daily vitamin E intake to under 400 IU when using Vascepa.
Provided excerpts do not provide any vitamin E dose limit.
The risk appears mainly when supplements are taken at large doses or for extended periods.
Provided excerpts do not specify timing/duration or dose-threshold characteristics for supplement-related bleeding risk.
Low-dose multivitamins normally do not create problems when used with Vascepa.
Provided excerpts do not address multivitamins or any reassurance about low-dose use.
Any new supplement should be cleared through a pharmacist or physician before use when using Vascepa.
Provided excerpts do not contain this general counseling instruction for 'any new supplement' specifically.
Amarin Pharma developed Vascepa.
The provided label excerpts do not mention the developer company.
Vascepa patent protection ended earlier than expected after court rulings in 2020.
The provided label excerpts do not mention patents or court rulings.
Contradictions
Important Omissions
No mention that VASCEPA bleeding risk is increased and is greater with concomitant antithrombotic medications (aspirin, clopidogrel, warfarin) and that patients should be monitored for bleeding when receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple concrete supplement-specific bleeding-risk and vitamin E dosing-limit claims are not supported by the provided label excerpts, which could mislead patients or clinicians regarding which supplements are risky and what monitoring or dose limits to apply.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements about specific supplements/herbs (garlic, ginkgo, dong quai, ginger, ginseng) and vitamin E dosing/physiology/bleeding-time effects are not supported by the provided VASCEPA label excerpts. The only on-label support provided is general increased bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents, not these specific supplements or a vitamin E <400 IU limit.
Suggested Improvement
Restrict interaction/bleeding statements to what the label excerpts support (increased bleeding risk; higher incidence with concomitant antithrombotic meds such as aspirin/clopidogrel/warfarin; monitor for bleeding when VASCEPA is used with anticoagulants and/or antiplatelet agents). Remove or qualify named supplement-specific and vitamin E dose-limit claims unless corresponding on-label text is supplied.